[Analysis of clinical and pathological features of chronic hepatitis B with hepatic steatosis].
OBJECTIVE
To explore clinical and pathological features of chronic hepatitis B (CHB) with hepatic steatosis.


METHODS
Retrospective analysis of hepatic steatosis in patients with liver biopsy-proven CHB between January 2005 and June 2008. Detailed clinical, laboratory and pathological data of CHB patients with steatosis were compared with those in sex-, age- matched CHB patients without steatosis. Patients co-infected hepatitis C virus or HIV or suffering from liver diseases of other causes were excluded.


RESULTS
Histological hepatic steatosis was found in 33.4% of the 1263 CHB patients. The prevalence of steatosis was increased with time in the study period (20.3%, 28.2%, 32.6%, 65.4%, in trend analysis, P values less than 0.05). Body mass index, fasting plasma glucose, serum triglyceride and total cholesterol level in CHB patients with hepatic steatosis (n = 114) were significantly higher than those in 113 patients without steatosis (t values were 6.811, 2.733, 3.063, 2.340, respectively, P values less than 0.01 or 0.05). Compared to patients without steatosis, serum hepatitis B virus DNA titer in patients with steatosis was significantly lower (x2 = 6.154, P less than 0.05) and reduced sharply with the increased degree of hepatic steatosis (x2 = 4.941, P less than 0.05). There were no differences in liver biochemical test (t values were 0.744, 1.390, -0.029, -1.175, 1.393, respectively, P values more than 0.05), hepatic inflammation grade and fibrosis stage between CHB patients with and without steatosis (x2 = 1.434, 0.106, respectively, P more than 0.05), and these parameters were not associated with different degree of hepatic steatosis (x2 = 2.447, 2.911, respectively, P more than 0.05).


CONCLUSIONS
Hepatic steatosis is common in patients with CHB, and is related to metabolic disorders. Hepatic steatosis does not affect the severity of CHB. The reverse association of hepatitis B virus titer with the degree of hepatic steatosis needs further investigation.
Mi
Yu-qiang
YQ
Tianjin Infectious Diseases Hospital, Tianjin Institute of Liver Disease, Tianjin 300192, China.
Liu
Yong-gang
YG
Xu
Liang
L
Fan
Jian-gao
JG
Zhang
Hong
H
Ping
Lei
L
Shi
Rui-fang
RF
D000410:Alanine Transaminase / Q000097:blood; D015415:Biomarkers / Q000097:blood; D015992:Body Mass Index; D002784:Cholesterol / Q000097:blood; D004279:DNA, Viral / Q000097:blood*; D005234:Fatty Liver / Q000453:epidemiology / Q000209:etiology / Q000473:pathology*; D005260:Female; D006515:Hepatitis B virus; D019694:Hepatitis B, Chronic / Q000150:complications / Q000473:pathology* / Q000821:virology; D006801:Humans; D008099:Liver / Q000473:pathology* / Q000821:virology; D008103:Liver Cirrhosis / Q000453:epidemiology / Q000209:etiology / Q000473:pathology; D008297:Male; D009765:Obesity / Q000150:complications; D012189:Retrospective Studies; D012307:Risk Factors; D012720:Severity of Illness Index
D015415:Biomarkers; D004279:DNA, Viral; D002784:Cholesterol; D000410:Alanine Transaminase